Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / SEMAGLUTIDE
FDA-approvedHigh for approved indication
Semaglutide
ALSO KNOWN ASWegovy · Ozempic · Rybelsus
A GLP-1 receptor agonist with strong outcome data for defined metabolic indications.
01CATEGORYMetabolic & fat loss
02REGULATORY STATUSFDA-approved
03COMMON ROUTESubcutaneous injection; an oral tablet exists for selected indications
04REVIEW STANDARDProduct, indication and evidence
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Semaglutide is.
A long-acting peptide analog of glucagon-like peptide-1. Different branded products have different indications, formulations and dose schedules; they are not interchangeable simply because the active ingredient is related.
HOW IT IS THOUGHT TO WORK
Activates GLP-1 receptors, increasing glucose-dependent insulin signaling, reducing glucagon when glucose is elevated, slowing gastric emptying and changing appetite signaling.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Substantial average weight reduction in eligible adults when paired with long-term lifestyle care
- Improved glycemic control in type 2 diabetes
- Cardiovascular risk reduction for specific labeled populations
- A universal weight-loss drug for anyone wanting to be leaner
- A substitute for resistance training, adequate protein or clinical follow-up
- That compounded or salt-form products are equivalent to FDA-approved brands
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Weight trajectory, waist and functional goals
- Glucose and diabetes-medication adjustment when relevant
- Hydration, GI tolerance and gallbladder symptoms
- Lean-mass preservation through nutrition and resistance training
SAFETY
Risks, red flags and reasons to avoid it.
- Nausea, vomiting, diarrhea, constipation and abdominal pain
- Gallbladder disease, pancreatitis warning and dehydration-related kidney injury
- Hypoglycemia when combined with insulin or insulin secretagogues
- Boxed thyroid C-cell tumor warning; contraindicated with personal/family MTC or MEN2
- Pregnancy
- Personal or family history of medullary thyroid carcinoma or MEN2
- Using multiple GLP-1 drugs together
- Unverified products sold without a lawful prescription
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Prescription-only FDA-approved products. FDA states compounded drugs are not FDA-approved and has warned about dosing errors, salt forms and misleading equivalence claims.
The molecule has high-quality evidence; product provenance still matters. A vial marketed as semaglutide is not automatically equivalent to a branded, approved product.
Compare qualified specialists
Coming soon: indication-matched clinicians, transparent pricing, required monitoring and verified prescription sourcing.
Join the treatment shortlist →NEXT STEP